This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Columbia University, Revolution Medicines, Inc., The University of North Carolina at Chapel Hill. Active years: 2026.
Company Filing History:
1 out of 2,551 
1 out of 40 
1 out of 1,325 
Years Active: 2026
Title: Kenneth Paul Olive: Innovator in Cancer Treatment
Introduction
Kenneth Paul Olive is a notable inventor based in New York, NY (US). He has made significant contributions to the field of cancer treatment, particularly in addressing challenges related to pancreatic cancer. His innovative approach has led to the development of a unique patent that aims to improve therapeutic outcomes for patients.
Latest Patents
Kenneth Paul Olive holds a patent titled "MYC amplification drives resistance to pan-RAS inhibitors in pancreatic cancer." This patent outlines methods of treating tumors in subjects by administering a combination of a RAS inhibitor and a TEAD inhibitor. The methods described are effective in treating tumors resistant to RAS inhibitor therapy, showcasing Olive's commitment to advancing cancer treatment methodologies.
Career Highlights
Throughout his career, Kenneth has worked with prestigious institutions, including Columbia University and The University of North Carolina at Chapel Hill. His work in these environments has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
One of his notable coworkers is Urszula Wasko. Their collaboration has likely fostered innovative ideas and advancements in their shared field of research.
Conclusion
Kenneth Paul Olive's contributions to cancer treatment through his patent and collaborations with esteemed institutions highlight his role as an influential inventor. His work continues to pave the way for new therapeutic strategies in the fight against pancreatic cancer.